{
	"ASSERTION": {
		"id": 2, 
		"context": "Chronic phase", 
		"description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for newly diagnosed patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. It is also approved for adults with chronic, accelerated, myeloid, or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. ", 
		"disease": {
			"name": "Chronic Myelogenous Leukemia", 
			"oncotree_code": "CML", 
			"oncotree_term": "Chronic Myelogenous Leukemia"
		}, 
		"therapy_name": "Dasatinib", 
		"therapy_type": "Targeted therapy", 
		"clinical_significance": "sensitivity", 
		"predictive_implication": "FDA-Approved", 
		"feature_ids": [2], 
		"favorable_prognosis": null, 
		"created_on": "01/07/21", 
		"last_updated": "2020-11-12", 
		"submitted_by": "breardon@broadinstitute.org", 
		"validated": true, 
		"source_ids": [2], 
		"variant": {
			"feature_type": "rearrangement", 
			"feature_id": 2, 
			"rearrangement_type": "Fusion", 
			"gene1": "BCR", 
			"gene2": "ABL1", 
			"locus": null, 
			"feature": "BCR--ABL1 Fusion"
		}
	}, 
	"SOURCE": {
		"id": 2, 
		"type": "FDA", 
		"assertion_id": [2, 3], 
		"doi": null, 
		"nct": null, 
		"pmid": "None", 
		"url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf", 
		"citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020."
	}, 
	"VARIANT": {
		"feature_type": "rearrangement", 
		"feature_id": 2, 
		"rearrangement_type": "Fusion", 
		"gene1": "BCR", 
		"gene2": "ABL1", 
		"locus": null, 
		"feature": "BCR--ABL1 Fusion"
	}
}